HORIZON-HLTH-2024-DISEASE-08-20 Pandemic preparedness and response - A SME partner for biomarkers and vaccine delivery systems for viral T cell vaccine development is sought.

Summary

Profile Type: Research & Development Request
POD Reference: RDRFR20240126017
Term of Validity: 26 January 2024 - 25 January 2025
Company's Country: France
Type of partnership: Research and development cooperation agreement
Targeted Countries: All countries

Contact the EEN partner nearest to you for more information.

Find my local partner

General information

Short Summary: The project aims to develop therapeutics and vaccines that help minimize the effect of the antibody-dependent enhancement (ADE) phenomenon. Together, the partners will develop a new generation of dengue vaccine and monoclonal antibodies for therapeutics and passive immunisation. The French research institute is currently looking for an SME with expertise in monoclonal antibody production and modification.
Full Description: The French research institute is dedicated to the study of biology, micro-organisms, diseases, and vaccines. It has been at the forefront of the fight against infectious diseases since its creation in the 19th century.

The project has 3 specific aims:
1. Understand the mechanism of ADE
2. Understand the factors influencing the ADE phenomenon
3. Develop therapeutics and passive immunization based on monoclonal antibodies

To well-answer the HORIZON-HLTH-2024-DISEASE-08-20 call, the French institute is looking for an SME with expertise in monoclonal antibody production and modification for therapeutics and passive immunization.
Advantages and Innovations: The advantages of the new dengue vaccine and monoclonal antibody and passive immunization are
1. Avoiding and minimizing side effects induced by antibodies such as antibody-dependent enhancement (ADE) which is an important factor for the development of severe dengue.
2. Well-balanced immuno-protection against all 4 dengue serotypes.
3. Long-lived immunity from T follicular helper cells.
4. Possibility to add T cell epitopes of other viruses in one component.
5. No safety issues due to ADE for dengue seronegative travelers to dengue endemic regions.
Stage of Development: Concept stage
Sustainable Development Goals: Goal 3: Good Health and Well-being
IPR description: Monoclonal antibody production and modification

Partner Sought

Expected Role of a Partner: They are currently looking for a company primarily with expertise in biomarkers and vaccine delivery systems. The company has to be a small and medium-sized enterprise, SME.

The expected role is monoclonal antibody production and modification.
Type and Size of Partner: SME 50 - 249SME 11-49SME <=10
Type of partnership: Research and development cooperation agreement

Call details

Framework program: Access to finance
Call title and identifier: HORIZON-HLTH-2024-DISEASE-08-20
Pandemic preparedness and response: Host-pathogen interactions of infectious diseases with epidemic potential
Submission and evaluation scheme: Single-stage submission scheme
Anticipated project budget: 7 to 8 million
Coordinator required: No
Deadline for EoI: 5 Apr 2024
Deadline of the call: 11 Apr 2024
Project duration in weeks: 260
Web link to the call: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportuni…
Project title and acronym: Viral T cell vaccine

Dissemination

Technology keywords: 06001006 - Human vaccines06001018 - Virus, Virology/Antibiotics/Bacteriology06002004 - Protein Engineering06002001 - Biochemistry / Biophysics06002009 - Molecular design
Market keywords: 04002 - Monoclonal Antibodies and Hybridomas04007 - Enzymology/Protein Engineering/Fermentation04005 - Biochemistry / Biophysics04011 - Molecular design
Sector Groups Involved: Health
Targeted countries: All countries